Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: zoledronic acid.
- Who it may be relevant to
- Registry conditions: Congenital Dyserythropoietic Anemia (CDA). Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia: An Exploratory Study
Overview
Background: Congenital Dyserythropoietic Anemia (CDA) is a group of rare hereditary blood disorders characterized by ineffective erythropoiesis, leading to chronic anemia and organ damage. Current treatment options are very limited, mainly relying on regular blood transfusions, which can cause severe complications over time. Our laboratory research and animal models suggest that Zoledronic acid, a medication commonly used for bone health, may improve ineffective erythropoiesis. Purpose: The purpose of this exploratory study is to evaluate the efficacy and safety of Zoledronic acid in adult patients with CDA who do not have other effective treatment options. The primary goal is to see if this treatment can increase hemoglobin levels and reduce the need for blood transfusions. Study Design: This is a prospective, single-center, single-arm study. Participants will receive an initial intravenous dose (4 mg) of Zoledronic acid. After a 4-week observation period to ensure safety, participants will receive additional doses every 4 weeks for a total of 4 doses. Researchers will monitor hemoglobin levels, transfusion frequency, spleen size, and overall quality of life over a period of 12 to 24 weeks.
Interventions
- Drug zoledronic acid
Zoledronic acid will be administered at a dose of 4 mg via a standardized intravenous (IV) infusion lasting no less than 15 minutes. To ensure safety, the initial dose is followed by a 4-week rigorous observation period. If the treatment is well-tolerated without significant adverse events, subsequent doses will be given every 28 days for a total of 4 cycles. Patients will be closely monitored for serum calcium levels and renal function (eGFR) throughout the intervention period to mitigate poten
Primary outcome measures
- Change in Hemoglobin Level From Baseline [Time frame: 12 weeks after the first dose]
Secondary outcome measures (4)
- Change in Hemoglobin Level at 4 Weeks [Time frame: 4 weeks after the first dose]
- Change in Red Blood Cell Transfusion Interval [Time frame: Up to 24 weeks]
- Change in Spleen Size [Time frame: Up to 24 weeks]
- Change in Quality of Life Assessed by the 36-Item Short Form Health Survey (SF-36) [Time frame: Up to 24 weeks]
Eligibility criteria
Inclusion criteria
- Age ≥ 18 years, regardless of gender.
- Diagnosis of Congenital Dyserythropoietic Anemia (CDA) based on clinical presentation, laboratory tests, and family investigation, with the presence of RBM28 mutation and/or increased vacuolization within nucleated red blood cells under light microscopy of bone marrow.
- Presence of anemia (Hemoglobin < 100 g/L at screening) or transfusion dependence (defined as an average transfusion interval of < 8 weeks within the past 3 months).
- Performance status is acceptable (ECOG score 0-2).
- Normal renal function (estimated glomerular filtration rate, eGFR ≥ 60 mL/min/1.73m²).
- Serum calcium levels within the normal range.
- Female patients of childbearing potential must have a negative pregnancy test before enrollment and agree to use effective contraception during the study and for 3 months after completion.
- The patient and/or guardian voluntarily sign the informed consent form.
Exclusion criteria
- Known hypersensitivity to bisphosphonates or any of their excipients.
- Severe periodontal disease or a recent history (within 6 months) of osteonecrosis of the jaw.
- Hypocalcemia.
- Pregnant or lactating women.
- Currently receiving other experimental drug treatments that may affect erythropoiesis (e.g., Luspatercept).
- Active, uncontrolled systemic infection.
- Severe cardiac, pulmonary, or hepatic dysfunction, as judged by the investigator to be unsuitable for participation in the study
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 1 center
- Institute of Hematology & Blood Diseases Hospital — Tianjin
Identifiers
NCT: NCT07471516 · IIT2025152